Cediranib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	17	2	10	100	—	—	2003-02
Malignant Cervical Neoplasm	Phase3	Phase 3	6	0	2	8	—	—	2010-02
Malignant Ovarian Neoplasm	Phase3	Phase 3	5	0	4	16	—	—	2005-10
Malignant Lung Neoplasm	Phase3	Phase 3	2	0	2	15	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRCA1 Mutation1
Cediranib + Olaparib

Clinical trials

Trials with this intervention (100)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 100 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02498613	A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	active not recruiting	Phase 2	122	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT03741426	WIRE - Novel Treatments in Renal Cell Cancer(WIRE)	recruiting	Phase 2